Generation of alloreactive anti-leukemic cytotoxic T lymphocytes with attenuated GVHD properties from haploidentical parents in childhood acute lymphoblastic leukemia

Bone Marrow Transplantation

Volumn 30, Issue 10, 2002, Pages 687-697

  Jurickova, I ^a   Waller, E K ^a   Yeager, A M ^a   Boyer, M W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Cellular immunotherapy; Cytotoxic T lymphocytes (CTL); Graft versus leukemia (GVL); Lymphokines

Indexed keywords

CD8 ANTIGEN; CONCANAVALIN A; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOIMMUNITY; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IRRADIATION; MONONUCLEAR CELL; PARENT; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; CASE REPORT; CELL DIVISION; COCULTURE; CYTOLOGY; CYTOTOXICITY; DRUG EFFECT; FEMALE; GAMMA RADIATION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOTYPE; IMMUNOLOGY; INFANT; LYMPHOCYTE ACTIVATION; MALE; METHODOLOGY; PATHOLOGY; PRESCHOOL CHILD; RADIATION EXPOSURE; TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; CELL DIVISION; CHILD; CHILD, PRESCHOOL; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GAMMA RAYS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HAPLOTYPES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LYMPHOCYTE ACTIVATION; MALE; PARENTS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 0036861225     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703718     Document Type: Article

References (31)

1. Woods WG, Kobrinsky N, Buckley JD et al. Timed-sequential induction therapy improves post remission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996; 87: 4979-4989.
2. Barrett AJ, Horowitz MM, Pollock BH et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. New Engl J Med 1994; 331: 1253-1258.
3. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
4. Smith WM, Rijnbeek M, van Bergen CAM et al. T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 1998; 95: 10152-10157.
5. Passweg JR, Tiberghien P, Cahn J-Y et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21: 153-158.
6. Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208.
7. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med 1998; 339: 1186-1193.
8. Henslee-Downey PJ, Abhyankar SH, Parrish RS et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-3872.
9. Handgretinger R, Schumm M, Lang P et al. Transplantation of megadoses of purified haploidentical stem cells. Ann NY Acad Sci 1999; 872: 351-361; discussion 361-362.
10. + cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 1999; 13: 2070-2078.
11. Johnson BD, Becker EE, Truitt RL. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant 1999; 5: 123-132.
12. Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176: 1283-1289.
13. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968; 14: 181-196.
14. Zheng Z, Takahashi M, Aoki S et al. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. J Exp Clin Cancer Res 1998; 17: 251-258.
15. Van den Hove LE, Van Gool SW, Vandenberghe P et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997; 11: 572-580.
16. Cardoso AA, Schultze JL, Boussiotis VA et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996; 88: 41-48.
17. Frisan T, Donati D, Cervenak L et al. CD40 cross-linking enhances the immunogenicity of Burkitt's lymphoma cell lines. Int J Cancer 1999; 83: 772-779.
18. Chouaib S, Chehimi J, Bani L et al. Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994; 91: 12659-12663.
19. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
20. Schmaltz C, Alpdogan O, Horndasch KJ et al. Differential use of Fas ligand and perform cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2000; 97: 2886-2895.
21. Waller EK, Ship AM, Mittelstaedt S et al. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood 1999; 94: 3222-3233.
22. Fowler DH, Breglio J, Nagel G et al. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol 1996; 157: 4811-4821.
23. Fowler DH, Gress RE. GVHD as a Th1-type process: Regulation by cells of Th2 cytokine phenotype. In: Burakoff S, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment, 2nd edn. Marcel Decker Inc: New York, pp 479-500.
24. Boyer MW, Johnson TS, Yeager AM et al. Allogeneic lymphocytes can mediate graft-versus-leukemia without causing graft-versus-host disease. Blood 1996; 88: 244a.
25. Kusunoki Y, Chen W, Martin PJ. Prevention of marrow graft rejection without induction of graft-versus-host disease by a cytotoxic T-cell clone that recognizes recipient alloantigens. Blood 1998; 91: 4038-4044.
26. Sallusto F, Lenig D, Forster R et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
27. Boussiotis VA, Barber DL, Nakarai T et al. Prevention of T cell anergy by signalling through the γc chain of the IL-2 receptor. Science 1994; 266: 1039-1042.
28. Biedermann BC, Pober JS. Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL. J Immunol 1999; 162: 7022-7030.
29. Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. New Engl J Med 2000; 343: 1020-1034.
30. Dailey MO, Gallatin WM, Weissman IL. The in vivo behavior of T cell clones: altered migration due to loss of the lymphocyte surface homing receptor. J Mol Cell Immunol 1985; 2: 27-36.
31. Li B, New JY, Yap EH et al. Blocking L-selectin and α4-integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease. Eur J Immunol 2001; 31: 617-624.